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countries, particularly depending on ethnicity and level of participation in the BCS 
programme. The model predicted a significant increase in the number of deaths 
associated with BC in Korea; a disinvestment decision, however, would not have a 
large impact on the number of deaths, due to currently high levels of overdiagno-
sis, and overall costs would be significantly reduced. A disinvestment decision in 
Australia would dramatically reduce the number of overdiagnosed women, although 
mortality due to BC would be higher. ConClusions: This analysis has shown that 
the cost-effectiveness of BCS programmes should be evaluated over the long-term 
in order to take into account the consequence of overdiagnosis. Disinvestment 
decisions are complex and must be made locally, taking into consideration specific 
characteristics of the population under study.
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objeCtives: Trastuzumab, a monoclonal antibody, has been widely used in treat-
ment of HER2-positive breast cancer because of its proved effectiveness and safety. 
However because of the high price, the cost-effectiveness of trastuzumab should 
be evaluated especially in such low-income country as Vietnam. This is also the 
aim of this study. Methods: A Markov model has been constructed with 5 health 
states (disease-free survival, local recurrence, regional recurrence, metastatic, 
death) with 1-year cycle length and lifetime horizon. The transition rates between 
states have been retrieved from relevant epidemiological studies, clinical trials and 
experts’ opinions. A population of 1000 50-year-old women with average weight of 
60 kg has been included in model. Lists of medical services and drugs were derived 
from NCCN guideline 2014. The prices of drugs and medical services have been 
averaged from the price-lists in 2013 of some major hospitals in Vietnam. Both 
QALYs and cost were discounted at 3%. Probabilistic sensitivity analysis was also 
conducted. Results: 1-year trastuzumab adjuvant therapy of HER2-positive early-
stage breast cancer costed VND 936,459,291.67 for life-time horizon and resulted 
in 10.07 QALYs. Standard chemotherapy costed VND 227,092,425 and resulted in 
7.32 QALYs. Therefore 1-year trastuzumab adjuvant therapy costed an addition 
amount of VND 709,4 million and resulted in added QALY of 2,75 years. CER of 
trastuzumab group is 3 times higher than no trastuzumab group (VND 91 million vs 
30 million, respectively). The incremental cost-effectiveness ratio (ICER) resulted in 
VND 265,115,616.93. One-year trastuzumab adjuvant therapy has been considered 
to be cost-effective when comparing with willing-to-pay (WTP) of Vietnam (VND 
253,503,360.00). Sensitivity analysis showed that the most affecting factor on the 
cost-effectiveness of trastuzumab is its price. ConClusions: 1-year trastuzumab 
adjuvant therapy of HER2-positive early-stage breast cancer is cost-effectiveness in 
Vietnam. Trastuzumab’s price is the most affecting factor on its cost-effectiveness.
PCN17
Cost EffECtivENEss ANAlysis of ANtidEPrEssANts oN brEAst CANCEr 
PAtiENts: A mArKov modEliNg study
Jiao T
University of Utah, Salt Lake City, UT, USA
objeCtives: With the developing of new technology for genetic test, the accuracy 
of predicting the risk that a patient may diagnose with breast cancer in future was 
increased dramatically. But considering that after diagnosis with breast cancer, 
those women has doubled prevalence of diagnosed with depression compared with 
general female population, and the anxiety patient suffered after realized taking 
specific mutations, which high likely led to breast cancer, before really diagnosed 
with breast cancer. There is no doubt that depression is a serious issue for patient 
with high risk of developed breast cancer. Moreover, the drug interaction between 
antidepressants and tamoxifen reduces the effect of tamoxifen, and complicates 
the decision-making. This cost-effectiveness study tries to use Markov model to 
investigate the best strategy that gives to high-risk breast cancer patients after 
genetic test and diagnosed with breast cancer. Methods: A cost-effectiveness 
study using Markov model will be conducted from a third payer perspective. Both 
time and different antidepressants from desipramine, fluoxetine, paroxetine, mian-
serin, melatonin to escitalopram will be included in this study as different expo-
sure. Life-long quality of life will be calculated as outcome. In order to investigate 
the extent of accuracy, one way sensitivity analyses and probabilistic sensitivity 
analysis will be conducted. Results: Mianserin, melatonin does not interfere with 
tamoxifen treatment, under that situation, these medication have the best outcome. 
The time period from diagnosed with breast cancer till 1 year is the best timing to 
give antidepressants, which may significantly change the outcome. ConClusions: 
Even though, sometimes patients with breast cancer may not realize they already 
threaten by depression, the antidepressant still significantly important to breast 
cancer population to prevent the progression of depression with better outcome.
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objeCtives: To evaluate the cost-effectiveness of nodal staging surgery before 
chemoradiotherapy (CRT) for locally advanced cervical cancer (LACC) in the era 
of PET/CT. Methods: A modified Markov model was constructed to evaluate cost 
effectiveness of para-aortic staging surgery before definite CRT when no uptake is 
recorded in para-aortic lymph nodes (PALN) on PET-CT. Survival and rates of compli-
cations were estimated based on the published literatures. Cost data was obtained 
from Korean National Health Insurance database. Strategies were compared using 
an incremental cost-effectiveness ratio (ICER). Sensitivity analyses were performed 
including an estimate for performance of PET/CT, postoperative complication rate, 
estimates were based on results of clinical studies and on information from the list 
of medical and economic charges of Republic of Kazakhstan (2009 y) and the retail 
price of pharmacies in Karaganda. Data sources: PubMed, the Cochrane library, 
Internet search was performed to analyze the results of clinical studies of treat-
ment patients with breast cancer. Results: One-year survival rate was higher by 
21.8% in patients receiving chemotherapy with “Arglabin” compared with patients 
receiving chemotherapy alone. Indicator “cost-effectiveness” for the scheme with 
Arglabin was 281,8 (the cost of one course of treatment is 281,8 $ on one survivor 
patient). Indicator “cost-effectiveness” for the standard scheme CMF was 367,5 (the 
cost of one course of treatment is 367,5$ on one survivor patient). ConClusions: 
The study was identified efficiency and economic benefit of therapy with “Arglabin”. 
Arglabin is effective and safety as additional agent to standard treatment and the 
implementation of this drug to standard therapy of breast cancer will improve the 
outcomes and reduce the costs.
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objeCtives: Number of expensive anti-cancer drugs is increasing. It is impor-
tant to assess cost-effectiveness of such high-cost drugs, however cost data, 
which is applicable to economic evaluation, are not accumulated enough in Japan. 
Therefore we analyzed large claim database to obtain treatment costs for breast 
cancer. Methods: We used JMDC (Japan Medical Data Center) claims database, in 
which claim data of approximately 1.5 million insured people are collected from 
January 2005 to September 2013. We analyzed treatment costs of (a) adjuvant chemo-
therapy, (b) hormone therapy and (c) chemotherapy for metastasis. Breast cancer 
was defined by disease name including claim date (C50 of ICD-10). Since no ICD-10 
code directly indicates metastatic breast cancer, combination of codes such as C780 
(metastasis to lung), C787 (to liver) and C793 (to brain) was used to extract meta-
static patients. We calculated monthly average costs and total costs for treatment 
period. Results: Approximately 400 patients receiving adjuvant chemotherapy 
were identified. Use of taxane (+ JPY 450,000 [USD 4,500, USD1 = JPY100])), trastu-
zumab (+ JPY 2.2 million [USD 22,000]) and hormone therapy (+ JPY 300,000 [USD 
3,000]) significantly influenced on the treatment costs per patient. Most frequently 
administered regimens were DC (D: Docetaxel, C: Cyclophosphamide), FEC+D (F: 
5-FU, E: Epirubicine) EC+D, and FEC. Costs of hormone therapy for metastatic breast 
cancer was averagely about JPY 110,000 [USD 1,100] per month. Tamoxifen was most 
widely used drug, followed by letrozole, anastorozole and exermestan. Average costs 
of chemotherapy was JPY 180,000 [USD 1,800] per month for patients without receiv-
ing molecular targeting therapy. It increased to JPY 360,000 [USD 3,600] per month if 
molecular targeting drugs were used. ConClusions: We can estimate treatment 
costs of breast cancer from the large Japanese claim database. These data are useful 
when cost-effectiveness analysis is performed.
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objeCtives: Organised, nationwide screening for breast cancer with mammogra-
phy in the age group 45-65 years with 2 years screening interval started in Hungary 
in January 2002. The aim of this study is to analyze the health insurance expen-
ditures of breast cancer treatment. Methods: The data derive from the financial 
database of the National Health Insurance Fund Administration (NHIFA) covering 
the 2010 year. The analysis of health insurance costs included outpatient costs of 
mammography screening, hospital costs of breast surgery, the cost of kemo- and 
radiotherapy. Results: The total annual health insurance cost of the National 
Health Insurance Fund Administration is estimated 12.09 billion Hungarian Forint 
(HUF) or 58.09 million dollar (USD). Most of them (61.0 %) releted to the cost of 
chemotherapy (7.38 billion HUF or 35.46 million USD). The next largest cost item 
(20.9 %) is the cost of radiotherapy (2.53 billion HUF or 12.16 million USD). Surgical 
treatment (1.14 billion HUF or 5.47 million USD) of breast cancer and cost of mam-
mography screening (1.04 billion HUF or 5.00 million USD) represents both similar 
volume (9.4 and 8.6 % respectively). ConClusions: The costs related to breast 
cancer screening and treatment showed an increasing trend in the past years. The 
most important cost item is the cost of chemotherapy.
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objeCtives: Disinvestment decisions are made when existing health technologies 
do not fulfil criteria such as efficacy, effectiveness or safety. Breast cancer screening 
(BCS) using mammography is widely implemented; yet many studies show that a 
significant percentage of women are overdiagnosed and overtreated. The objective 
of this study is to analyse the effects of a BCS disinvestment decision in Asia-Pacific 
countries, and to explain any differences between countries. Methods: A math-
ematical model was developed to analyse population outcomes and costs associ-
ated with breast cancer (BC) from 2014 to 2050 in Australia and Korea. Population 
outcomes were measured as number of women diagnosed with BC, number of 
women overdiagnosed and number of deaths associated with BC. The model allowed 
the analysis of these outcomes with and without a BCS programme in place, as a 
proxy to evaluate the effects of disinvestment. Results: Results varied between 
